Compare LFUS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LFUS | CORT |
|---|---|---|
| Founded | 1927 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 9.7B |
| IPO Year | 1996 | 2001 |
| Metric | LFUS | CORT |
|---|---|---|
| Price | $414.09 | $81.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $496.25 | $141.00 |
| AVG Volume (30 Days) | 243.0K | ★ 881.3K |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.94 | 0.09 |
| Revenue | $757,853,000.00 | ★ $761,407,000.00 |
| Revenue This Year | $23.39 | $50.42 |
| Revenue Next Year | $11.04 | $46.34 |
| P/E Ratio | ★ $36.19 | $893.00 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $233.36 | $28.66 |
| 52 Week High | $500.57 | $126.38 |
| Indicator | LFUS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 26.90 |
| Support Level | $389.23 | $77.38 |
| Resistance Level | $428.88 | $122.93 |
| Average True Range (ATR) | 18.50 | 5.37 |
| MACD | 3.57 | -2.82 |
| Stochastic Oscillator | 93.85 | 8.75 |
Littelfuse is a supplier of circuit protection products (such as fuses and relays) for the transportation, industrial, telecommunications, and consumer electronics end markets. Littelfuse also holds a minority power semiconductor business, primarily serving high-voltage industrial applications. Littelfuse sells globally across both distribution and direct channels, and organizes its business into the three segments of electronics, transportation, and industrial. Littelfuse is a serial acquirer of smaller, bolt-on adjacent firms.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.